Literature DB >> 34198846

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer.

Luis Javier Martínez-González1, Victor Sánchez-Conde2, Jose María González-Cabezuelo3, Alba Antunez-Rodríguez1, Eduardo Andrés-León4, Inmaculada Robles-Fernandez5, Jose Antonio Lorente5,6, Fernando Vázquez-Alonso2, María Jesus Alvarez-Cubero5,7,8.   

Abstract

MiRNAs play a relevant role in PC (prostate cancer) by the regulation in the expression of several pathways' AR (androgen receptor), cellular cycle, apoptosis, MET (mesenchymal epithelium transition), or metastasis. Here, we report the role of several miRNAs' expression patterns, such as miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b, with relevance in processes like cell proliferation and MET. Using Trizol® extraction protocol and TaqMan™ specific probes for amplification, we performed miRNAs' analysis of 159 PC fresh tissues and 60 plasmas from peripheral blood samples. We had clinical data from all samples including PSA, Gleason, TNM, and D'Amico risk. Moreover, a bioinformatic analysis in TCGA (The Cancer Genome Atlas) was included to analyze the effect of the most relevant miRNAs according to aggressiveness in an extensive cohort (n = 531). We found that miR-210-3p, miR-23c, miR-592, and miR-93-5p are the most suitable biomarkers for PC aggressiveness and diagnosis, respectively. In fact, according with our results, miR-93-5p seems the most promising non-invasive biomarker for PC. To sum up, miR-210-3p, miR-23c, miR-592, and miR-93-5p miRNAs are suggested to be potential biomarkers for PC risk stratification that could be included in non-invasive strategies such as liquid biopsy in precision medicine for PC management.

Entities:  

Keywords:  aggressiveness; bioinformatic; biomarkers; precision medicine; prostate cancer

Year:  2021        PMID: 34198846     DOI: 10.3390/biomedicines9060646

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  5 in total

1.  miR-145-5p: A Potential Biomarker in Predicting Gleason Upgrading of Prostate Biopsy Samples Scored 3+3=6.

Authors:  Tao Wang; Lei Dong; Juanjuan Sun; Jialiang Shao; Jian Zhang; Siteng Chen; Chaofu Wang; Gangfeng Wu; Xiang Wang
Journal:  Cancer Manag Res       Date:  2021-12-10       Impact factor: 3.989

Review 2.  The Role of Androgen Receptor and microRNA Interactions in Androgen-Dependent Diseases.

Authors:  Agnieszka Bielska; Anna Skwarska; Adam Kretowski; Magdalena Niemira
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

3.  m6A Methylation Regulators Are Predictive Biomarkers for Tumour Metastasis in Prostate Cancer.

Authors:  Yingchun Liang; Xiaohua Zhang; Chenkai Ma; Jimeng Hu
Journal:  Cancers (Basel)       Date:  2022-08-21       Impact factor: 6.575

4.  Integrative Analysis and Experimental Validation Indicated That SNHG17 Is a Prognostic Marker in Prostate Cancer and a Modulator of the Tumor Microenvironment via a Competitive Endogenous RNA Regulatory Network.

Authors:  Jinling Li; Hongyuan Yu; Jinlong Yao; Zhenming Jiang; Zhenhua Li; Xiaolu Cui
Journal:  Oxid Med Cell Longev       Date:  2022-07-12       Impact factor: 7.310

Review 5.  Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs.

Authors:  Eva Slabáková; Zuzana Kahounová; Jiřina Procházková; Karel Souček
Journal:  Noncoding RNA       Date:  2021-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.